Stamford, CT -- (SBWIRE) -- 10/09/2013 -- Jet Life Penny Stocks provides investors with the Awesome Penny Stock alerts on a regular basis. We will send you alerts through our Penny Stock Newsletters and offer you the tools to help you along the way with the goal of keeping you loyal to our service. Have a look on today’s market movers: Callidus Software Inc.(NASDAQ:CALD), Yelp Inc(NYSE:YELP) , Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX), Direxion Shares Exchange Traded Fund Trust(NYSEARCA:NUGT),
Callidus Software Inc.(NASDAQ:CALD) increased 15.70% at the price of $9.95 recently on a traded volume of 1.98 million shares, in comparison to 405,448.00 shares of average trading volume. So far this year, the stock is up over 125%.
The company has a total market capitalization of $377.48 million and its total outstanding shares are 38.02 million. Callidus Software Inc., doing business as CallidusCloud, provides cloud-based solutions to companies worldwide. The company offers Sales Selector, which delivers a combination of online video interviewing, assessment testing, and social benchmarking for sales managers to evaluate candidates.
For How Long CALD will Fight for Profitability? Read This Trend Analysis report
Yelp Inc(NYSE:YELP) plunged -3.34% at the trading price of $62.44 on a traded volume of 2.20 million shares till now, whereas its average trading volume is 3.71 million shares. In the last three months, the stock is up 68.64%. The Intra-day range for the stock is $60.83 and $65.25. Yelp, Inc. operates Yelp.com, an online urban city guide that helps people find places to eat, shop, drink, relax, and play based on the informed opinions of a community of locals in the know.
Has YELP Found The Bottom And Ready To Gain Momentum? Find Out Here
Lexicon Pharmaceuticals, Inc.(NASDAQ:LXRX) dropped down -10.34% at the $2.43 recently. So far in three months, the stock is up 2.98%. The 52-week range for the stock is $1.55 and $3.18. Its introductory price for the day was $2.55, with the overall traded volume of 1.22 million shares. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes.
Why Should Investors Buy LXRX After the Recent Fall? Just Go Here and Find Out
Direxion Shares Exchange Traded Fund Trust(NYSEARCA:NUGT) after opening its shares at the price of $41.80, dropped -4.30% , its recent trading price was $41.00 for the day. The stock moved on a traded volume of 228,750.00 shares.
The 52-week range for the stock is $4.55 and $106.00. Its introductory price for the day was $41.80. Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes; LX1032, which is in Phase III clinical trials for the treatment of carcinoid syndrome and ulcerative colitis.
Why Should Investors Buy NUGT After The Recent Gain? Just Go Here and Find Out
Jet Life Penny Stocks is always searching the market every day for massive penny stock runs before they happen so you don't have to. Jet Life Penny Stocks also offers free Highly-Professional Grade stock charts and video charts from one of the most experienced and well-respected chartists in the penny stock industry.
Jet Life Penny Stocks is not a registered securities advisor. Investors should always conduct their own additional due diligence with any potential investment or highlighted company. The company provides information on highlighted stocks via press releases, newsletters and company website, but this should not be construed as a recommendation to buy or sell. Please visit the company website for a more complete list of risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)